FLEX-CP-DT: A Flexible Conditional Power Framework for Interim Futility Analysis in Clinical Trials with Count Endpoints and Temporal Trends
FLEX-CP-DT:计数终点与时间趋势下的期中无效性分析AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要主要研究临床计数终点的条件功效与期中停止设计,未直接对应给定的计量细分方向。
FLEX-CP-DT:计数终点与时间趋势下的期中无效性分析AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Many large-scale phase III trials with recurrent event endpoints include a pre-planned interim analysis to evaluate early futility. Conditional power (CP), which quantifies the probability of achieving statistical significance at the final analysis given the interim data, is a commonly used tool to support such decisions. The standard negative binomial model with an offset term, widely adopted for analyzing recurrent events, implicitly assumes that event rates and treatment effects remain constant over the study period. At the interim analysis, however, a substantial proportion of patients have incomplete follow-up, and when the treatment effect is delayed in onset or diminishes over time, the constant-rate assumption introduces systematic bias into the interim estimate and can lead to incorrect futility decisions. In this paper, we propose FLEX-CP-DT, a piecewise negative binomial framework that captures temporal trends in both event rates and treatment effects without imposing the constant-rate assumption. The framework yields a formula-based conditional power calculation that does not require resampling or trial simulation at the interim stage. Through extensive simulations spanning constant-effect and delayed-onset scenarios, we demonstrate that FLEX-CP-DT performs comparably to the standard approach when the constant-rate assumption holds and improves interim futility decision-making when it is violated. A case study calibrated to a published phase 3 bronchiectasis trial further illustrates the practical advantage of the proposed method in reducing the probability of falsely terminating an efficacious drug with delayed treatment onset.